Iselin-based Outlook Therapeutics, a biopharmaceutical leader, on Tuesday announced the strategic appointment of Laura Cantrell as vice president of Corporate Strategy and Business Development.
The move comes at a critical juncture for the company as it works to stabilize its U.S. regulatory path and expand its footprint in international markets. Reporting directly to CEO Bob Jahr, Cantrell will spearhead the firm’s business development, including strategic partnerships and licensing initiatives aimed at maximizing the value of its ophthalmic bevacizumab portfolio (treatment of retina diseases).
Cantrell brings over 20 years of high-impact biotechnology experience to Outlook. Her track record includes senior roles at industry giants like Genentech/Roche, BeiGene, and Medivation. Most notably, she was a core member of the team that facilitated Medivation’s $14 billion acquisition by Pfizer.
“Laura’s proven ability to identify and execute high-value opportunities will be instrumental as we advance our mission,” Jahr said. “We are welcoming her at a pivotal time in our evolution.”
As vice president of corporate strategy, Cantrell will likely focus on:
-
Strategic Partnerships: Seeking co-development or commercialization partners to share the costs of potential new U.S. clinical trials.
-
Portfolio Expansion: Exploring the use of ONS-5010 for other retinal diseases, such as Diabetic Macular Edema (DME) and Branch Retinal Vein Occlusion (BRVO).
-
Shareholder Value: Stabilizing investor confidence following the recent stock volatility.
“I am excited to join Outlook Therapeutics at such an important moment,” Cantrell added. “I look forward to leveraging my experience in global partnerships to support Outlook’s next phase of growth.”
